Lundbeck nelle notizie
Specializzato in malattie cerebrali
Tamtam ha trovato 20 articoli recenti su Lundbeck.
- Barclays raises Lundbeck price target to 50 Danish kroner (48), reiterates equal weight - BN
- Cradle & Lundbeck: Partnering on Biotherapeutics and AI
- Ugens danske Vindere og tabere: Torm, Norden og Lundbeck topper
- Lundbeck to highlight mechanistic insights on bexicaserin's dual mode of action at the European Epilepsy Congress
- Lundbeck moves from rebuilding to “scaling phase”, Jefferies says
- Lundbeck vil præsentere præklinisk data om epilepsikandidat i weekenden
- AprilBio's APB-A1 Development Resumes at Lundbeck with Shift to Neurological Diseases; Licensing Deal Value Intact
- H. Lundbeck (CPSE:HLUN B) After Strong Q2 Results Is The Stock A Bargain Or Priced Right
- Eversana rolls out expanded AI agency platform with client Lundbeck going all-in
- Secret Novo-Lundbeck collaboration helped seal Swedish CNS deal: "You have to move quickly"
- H. Lundbeck (CPSE:HLUN A) - Analyse des actions
- Lundbeck expands AI partnership for commercialization in the US
- Lundbeck gains EU orphan status for anti‑ACTH antibody
- Lundbeck receives coveted status for drug candidate in the EU
- Lundbeck, Eversana Expand AI Commercialization Partnership
- Lundbeck’s asedebart receives EC orphan designation in Cushing’s syndrome
- Lundbeck And Eversana Announce Strategic Partnership
- Lundbeck and EVERSANA partner to advance AI-powered commercialization
- Lundbeck får eftertragtet status til lægemiddelkandidat i EU
- Lundbeck and EVERSANA Announce Strategic Partnership to Advance AI-Powered Commercialization
Articoli raccolti da Tamtam e conservati quando riguardano l'azienda, dal più recente. Ognuno rimanda alla sua fonte.
Vendi ad aziende come Lundbeck?
Tamtam trova le aziende in linea con il tuo cliente ideale, analizza ogni account e ti dice chi contattare e quando.
Trova aziende simili